Cholecystokinin, glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity

Journal of Pediatric Endocrinology and Metabolism

Volumn 17, Issue 12, 2004, Pages 1623-1631

  Tomasik, Przemyslaw J ^b,c   Sztefko, Krystyna ^b   Starzyk, Jerzy ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c NONE   (Poland)

Author keywords

Anorexia nervosa; Cholecystokinin; Eating disorders; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Satiety factors; Simple obesity

Indexed keywords

CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ADOLESCENT; ANOREXIA NERVOSA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; EATING DISORDER; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HORMONE RELEASE; HUMAN; NAUSEA AND VOMITING; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; POSTPRANDIAL STATE; RADIOIMMUNOASSAY; SCHOOL CHILD; STOMACH EMPTYING;

EID: 11044228314     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2004.17.12.1623     Document Type: Article

References (37)

1. Dietz W. Critical periods in childhood for development of obesity. Am J Clin Nutr 1994; 59: 955-959.
2. Halami KA. Eating disorders in females: genetics, pathophysiology and treatment. J Pediatr Endocrinol Metab 2002; 15 (Suppl 5): 1379-1386.
3. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-1152.
4. Anika M. Effects of cholecystokinin and cerulein on gastric emptying. Eur J Pharmacol 1982; 85: 195-199.
5. Adler G, Beglinger C, Braun U, Reinshagen M, Koop I, Schafmayer A, Rovati L, Arnold R. Interaction of the cholnergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans. Gastroenterology 1991; 100: 537-543.
6. Hildebrand P, Ensinck JW, Ketterer S, Delco F, Mossi S, Bangerter U, Beglinger C. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 1991; 72: 1123-1129.
7. Schmid R, Schusdziarra V, Schulte-Frohlinde E, Maier V, Classen M. Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans. Pancreas 1989; 4: 653-661.
8. Karlson S, Ahren B. Cholecystokinin and the regulation of insulin secretion. Scand J Gastroenterol 1992; 27: 161-165.
9. Rushakoff R, Goldfine I, Carter J, Liddle R. Physiological concentrations of cholecystokinin stimulate aminoacid induced insulin release in humans. J Clin Endocrinol Metab 1987; 65: 395-401.
10. Wolkowitz OM, Gertz B, Weingartner H, Beccaria L, Thompson K, Liddle RA. Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Biol Psychol 1990; 28: 169-173.
11. Kruszynska Y, Ghatei M, Bloom S, McIntyre R. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. Hepatology 1995; 21: 933-941.
12. Thomas FB, Mazzaferri EL, Crockett SE, Mekhjian HS, Gruemer HD, Cataland S. Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. Gastroenterology 1976; 70: 523-527.
13. Pederson R, Brown J. Inhibition of histamine, pentagastrin and insulin-stimulated canine gastric secretion by pure gastric inhibitory peptide. Gastroenterology 1972; 62: 393-400.
14. Simmons TC, Taylor IL, Maxwell V, Brown JC, Grossman MI. Failure of gastric inhibitory peptide to inhibit pentagastrin-stimulated acid secretion in vagotomized human subjects. Digest Dis Sci 1981; 26: 902-904.
15. Pederson R, Brown J. Interaction of gastric inhibitory polypeptide, glucose and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978; 103: 610-615.
16. Schirra. J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103.
17. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987; 30: 874-881.
18. Manaka H, Sugiyama K, Takahashi H. tGLP-1 release from isolated perfused canine ileum. Digestion 1990; 46 (Suppl 1): 66.
19. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 15: 390-407.
20. Kreymann B, Williams M, Ghatei M, Bloom S. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; ii: 1300-1303.
21. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107: 1848-1855.
22. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Molker M, Sheikh SP. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-856.
23. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide 1 in the central regulation of feeding. Nature 1996; 379: 69-72.
24. 131-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol 1999; 26: 413-420.
25. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
26. Naslund E, Gutniak M, Skogar S, Rosner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese man. Am J Clin Nutr 1998; 68: 525-530.
27. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-R1544.
28. McHugh P, Moran T. The stomach, cholecystokinin and satiety. Fed Proc 1986; 45: 1384-1390.
29. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792.
30. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G424-431.
31. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665-670.
32. Abell TL, Malagelada JR, Lucas AR, Brown ML, Camilleri M, Go VL, Azpiroz F, Callaway CW, Kao PC, Zinsmeister AR. Gastric electromechanical and neurohormonal function in anorexia nervosa. Gastroenterology 1987; 93: 958-965.
33. Pi-Sunyer X, Kissileff H, Thornton J, Smith G. C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 1982; 29: 627-630.
34. Baldwin B, Parrott R, Ebenezer I. Food for thought: a critique on the hypothesis that endogenous cholecystokinin acts as a physiological satiety factor. Prog Neurobiol 1998; 55: 477-507.
35. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
36. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20: 1616-1621.
37. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol 1999; 277: 46-45.